Skip to application
All calculators and tools
IV Dilution & Medication Referencev7.4
Back to resultsA-Z list

Alteplase

Depends on presentation or useFull monograph review pending

Jump to a section

Historical dilution reference. Verify the preparation against the label for the product in hand.

Original GlobalRPh article: Alteplase (opens in a new tab)Original source URL: https://globalrph.com/dilution/alteplase/ Retrieved 2026-11-04

Historical source details

Original publication date: unavailable in the retrieved article.

Source location and file checksums
Original source URL
https://globalrph.com/dilution/alteplase/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:45:43.196726+00:00
Source location
div.post-content
Packaged content SHA-256
27d28687e4dc26a444883577951da999717023ec708424cd3d6beb94cb0aebbd
Original response SHA-256
633be7627fb8220f2cd2d923708f186acdb39d7789100199ace65c20937107c3
Source body SHA-256
e125b055de2aed4ad1a1cb49e15ad702dcda4e1f7712e348843d7d5b2b48a2d4

Alteplase - (ACTIVASE, TPA)

The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read the disclaimer

Usual Diluents

NS, D5W

Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate]

Note: Sterile water without preservative
[50 mg vial] [50 ml - SW] [UD]
[100 mg vial] [100 ml - SW ] [UD]

Peripheral arterial occlusive disease: Continuous infusion of alteplase: 0.5 to 2 mg/hr x 6 to 72 hours depending on location. Preparation: Dilute alteplase with sterile water as above, then further dilute with NS to produce one of the following concentrations below:

Concentration (0.1 mg/ml)
[25 mg] [250ml]
[50 mg] [500 ml]

Concentration (0.2 mg/ml)
[50 mg] [250ml]

Alternatives:
-------------------------------------------
Concentration (0.025 mg/ml)
[12.5 mg] [500ml]

Concentration (0.05 mg/ml)
[25 mg] [500ml]

Stability / Miscellaneous

EXP: 8 hours (RT). Prepare just before use. Results in concentration of 1 mg/ml. May be infused at this concentration or may dilute further with equal volume of normal saline or D5W (0.5 mg/ml).

Stability data:

Drug Stability Refrigerated Stability Room Temp. Reconstituted Vial/Powder Notes P-Insert Updated
Alteplase Kit Store lyophilized Activase under refrigeration not to exceed (2-8°C/36-46°F). Protect the lyophilized material during extended storage from excessive exposure to light. If stored between 2-30°C (36-86°F), Activase may be used within 8 hours following reconstitution. Store lyophilized Activase at controlled room temperature not to exceed 30°C (86°F). Protect the lyophilized material during extended storage from excessive exposure to light. If stored between 2-30°C (36-86°F), Activase may be used within 8 hours following reconstitution. Kit Discard any unused solution after administration is complete. Do not use beyond the expiration date stamped on the vial. 02 24 15
Alteplase (TPA) Store lyophilized Cathflo Activase at refrigerated temperature (2-8°C/36-46°F). The solution may be used for intracatheter instillation within 8 hours following reconstitution when stored at 2-30°C (36-86°F). The solution may be used for intracatheter instillation within 8 hours following reconstitution when stored at 2-30°C (36-86°F). Powder Any unused solution should be discarded. Do not use beyond the expiration date on the vial. Protect the lyophilized material during extended storage from excessive exposure to light. 10 08 13

Dosing:
Acute MI
: (2 protocols)- (1) (Preferred) Accelerated infusion: for patients > 65kg: 15 mg IV bolus f/b 50mg over next 30min, and the remaining 35mg (100mg total) infused over the next 60 min. Patients <65kg: 15 mg bolus, then 0.75 mg/kg (max 50 mg) over 30 minutes, then 0.5 mg/kg (max 35 mg) over next 60 minutes. (2) 3-hour infusion (may be less effective): In 1st hour, 60 mg is administered (of which 6-10mg is administered ivpush in first 1-2 minutes), followed by 20 mg/hr x 2 hours. (100mg total). For patients <65 kg: administer 1.25 mg/kg in the same manner over 3 hours.

Pulmonary embolism: 100 mg over 2 hours.
Stroke
: (Give within first 3 hours): 0.9 mg/kg (max 90mg)-10% of dose given ivpush, followed by a continuous infusion over 1 hour.


Intracatheter: Cathflo® Activase® (Alteplase) is for instillation into the dysfunctional catheter at a concentration of 1 mg/mL.

DOSAGE AND ADMINISTRATION
• Patients weighing >/=30 kg: 2 mg in 2 mL.
• Patients weighing <30 kg: 110% of the internal lumen volume of the catheter, not to exceed 2 mg in 2 mL. If catheter function is not restored at 120 minutes after 1 dose of Cathflo Activase, a second dose may be instilled (see INSTRUCTIONS FOR ADMINISTRATION). There is no efficacy or safety information on dosing in excess of 2 mg per dose for this indication. Studies have not been performed with administration of total doses greater than 4 mg (two 2-mg doses). Package insert.

Instructions for Administration
Preparation of Solution:
Reconstitute Cathflo Activase to a final concentration of 1 mg/mL: Aseptically withdraw 2.2 mL of Sterile Water for Injection, USP (diluent is not provided). Do not use Bacteriostatic Water for Injection. Inject the 2.2 mL of Sterile Water for Injection, USP, into the Cathflo Activase vial, directing the diluent stream into the powder. Slight foaming is not unusual; let the vial stand undisturbed to allow large bubbles to dissipate. Mix by gently swirling until the contents are completely dissolved. Complete dissolution should occur within 3 minutes. DO NOT SHAKE. The reconstituted preparation results in a colorless to pale yellow transparent solution containing 1 mg/mL Cathflo Activase at a pH of approximately 7.3. Cathflo Activase contains no antibacterial preservatives and should be reconstituted immediately before use. The solution may be used for intracatheter instillation within 8 hours following reconstitution when stored at 2-30°C (36-86°F). No other medication should be added to solutions containing Cathflo Activase.

Instillation of Solution into the Catheter Inspect the product prior to administration for foreign matter and discoloration. Withdraw 2 mL (2 mg) of solution from the reconstituted vial. Instill the appropriate dose of Cathflo Activase (see DOSAGE AND ADMINISTRATION) into the occluded catheter. After 30 minutes of dwell time, assess catheter function by attempting to aspirate blood. If the catheter is functional, go to Step 7. If the catheter is not functional, go to Step 5. After 120 minutes of dwell time, assess catheter function by attempting to aspirate blood and catheter contents. If the catheter is functional, go to Step 7. If the catheter is not functional, go to Step 6. If catheter function is not restored after one dose of Cathflo Activase, a second dose of equal amount may be instilled. Repeat the procedure beginning with Step 1 under Preparation of Solution. If catheter function has been restored, aspirate 4-5 mL of blood in patients >/=10 kg or 3 mL in patients <10 kg to remove Cathflo Activase and residual clot, and gently irrigate the catheter with 0.9% Sodium Chloride Injection, USP. Any unused solution should be discarded.

Stability and Storage Store lyophilized Cathflo Activase at refrigerated temperature (2-8°C/36-46°F). Do not use beyond the expiration date on the vial. Protect the lyophilized material during extended storage from excessive exposure to light.

HOW SUPPLIED Cathflo Activase (Alteplase) for injection is supplied as a sterile, lyophilized powder in 2 mg vials. Each Cathflo®Activase® carton contains one 2 mg vial of Cathflo® Activase® (Alteplase): NDC 50242-041-64.


Intra-arterial: Acute peripheral arterial occlusive disease (unlabeled use): 0.02-0.1 mg/kg/hour for up to 36 hours Advisory Panel to the Society for Cardiovascular and Interventional Radiology on Thrombolytic Therapy recommendation: </=2 mg/hour and subtherapeutic heparin (aPTT <1.5 times baseline) Additional info

Open this historical article on its own

U.S. label preparation

Activase · Depends on presentation or use

Preparation
Systemic Activase only. Reconstitute the 50 mg or 100 mg vial with the matching supplied volume of preservative-free sterile water (50 or 100 mL) to make 1 mg/mL. The 100 mg kit uses the supplied transfer device. Cathflo 2 mg catheter clearance has separate instructions.
Administration and handling
Give at 1 mg/mL or dilute immediately before administration with an equal volume of 0.9% sodium chloride or 5% dextrose to 0.5 mg/mL. Use a PVC bag or glass vial. Select the indication-specific bolus and infusion regimen.
Product and source details

Genentech, Inc. · BLA103172

Product NDC: 50242-044, 50242-085

SPL effective 2026-01-20 | SPL version 15. Checked 2026-11-13.

Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.

Product identifiers and clinical review status

U.S. label preparation available. Full monograph review pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Obtain independent corroboration of the label preparation where available.
  • Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
  • Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.